URGN logo

UroGen Pharma (URGN) Cash From Investing

Annual CFI

-$20.61 M
-$19.66 M-2062.96%

December 31, 2024

Summary

Performance

1-Year Change

-2062.96%

3-Year Change

-606.59%

5-Year Change

+85.84%

15-Year Change

+43.18%

URGN Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

28.89%
URGN annual cash flow from investing activities is higher than 28.89% of companies in Healthcare sector

High & Low

All-time High

$93.24 M
URGN annual cash flow from investing activities is currently -122.11% below its historical high of $93.24 million

3-Year Low

-$20.61 M
URGN annual cash flow from investing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
URGN previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
URGN next annual earnings announcement has not yet been scheduled

OtherURGNcash flowmetrics:

Annual CFF

$194.62 M
URGN annual cash flow from financing activities is $194.62 million

Annual CFO

-$96.77 M
URGN annual cash flow from operations is -$96.77 million

Annual FCF

-$97.06 M
URGN annual free cash flow is -$97.06 million

Annual CAPEX

$295.00 K
URGN annual capital expenditures is $295.00 thousand

Quarterly CFI

$60.62 M
+$167.37 M+156.79%

December 31, 2024

Summary

Performance

3-Month Change

+156.79%

1-Year Change

+156.79%

3-Year Change

+564.34%

5-Year Change

+552.12%

URGN Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

95.57%
URGN quarterly cash flow from investing activities is higher than 95.57% of companies in Healthcare sector

High & Low

All-time High

$60.62 M
URGN quarterly cash flow from investing activities is currently at an all-time high

3-Year Low

-$106.75 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
URGN previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 13, 2025
URGN next earnings announcement is scheduled for May 13, 2025

OtherURGNcash flowmetrics:

Quarterly CFF

$71.00 K
URGN quarterly cash flow from financing activities is $71.00 thousand

Quarterly CFO

-$13.62 M
URGN quarterly cash flow from operations is -$13.62 million

Quarterly FCF

-$13.73 M
URGN quarterly free cash flow is -$13.73 million

Quarterly CAPEX

$115.00 K
URGN quarterly capital expenditures is $115.00 thousand

TTM CFI

-$20.61 M
+$71.97 M+77.73%

December 31, 2024

Summary

Performance

3-Month Change

+77.73%

1-Year Change

+77.73%

3-Year Change

-606.59%

5-Year Change

+85.84%

URGN TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

30.47%
URGN TTM cash flow from investing activities is higher than 30.47% of companies in Healthcare sector

High & Low

All-time High

$95.24 M
URGN TTM cash flow from investing activities is currently -121.64% below its historical high of $95.24 million

3-Year Low

-$92.58 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
URGN previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 13, 2025
URGN next earnings announcement is scheduled for May 13, 2025

OtherURGNcash flowmetrics:

TTM CFF

$194.62 M
URGN TTM cash flow from financing activities is $194.62 million

TTM CFO

-$96.77 M
URGN TTM cash flow from operations is -$96.77 million

TTM FCF

-$97.06 M
URGN TTM free cash flow is -$97.06 million

TTM CAPEX

$295.00 K
URGN TTM capital expenditures is $295.00 thousand

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

URGN Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-2063.0%+156.8%+77.7%
3 y3 years-606.6%+564.3%-606.6%
5 y5 years+85.8%+552.1%+85.8%

URGN Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-606.6%at lowat high+156.8%-161.5%+77.7%
5 y5-year-122.1%+85.8%at high+156.8%-121.6%+85.8%
alltimeall time-122.1%+85.8%at high+142.6%-121.6%+86.7%

UroGen Pharma Cash From Investing History

DateAnnualQuarterlyTTM
Dec 2024
-$20.61 M(+2063.0%)
$60.62 M(-156.8%)
-$20.61 M(-77.7%)
Sep 2024
-
-$106.75 M(-989.7%)
-$92.58 M(-735.3%)
Jun 2024
-
$12.00 M(-11.2%)
$14.57 M(+131.5%)
Mar 2024
-
$13.52 M(-219.2%)
$6.29 M(-760.5%)
Dec 2023
-$953.00 K(-189.9%)
-$11.34 M(-2928.9%)
-$953.00 K(-102.8%)
Sep 2023
-
$401.00 K(-89.2%)
$33.50 M(-1498.7%)
Jun 2023
-
$3.72 M(-40.7%)
-$2.40 M(-61.8%)
Mar 2023
-
$6.27 M(-72.9%)
-$6.27 M(-691.1%)
Dec 2022
$1.06 M(-73.9%)
$23.11 M(-165.1%)
$1.06 M(-108.2%)
Sep 2022
-
-$35.49 M(>+9900.0%)
-$12.92 M(-138.9%)
Jun 2022
-
-$151.00 K(-101.1%)
$33.23 M(+1158.2%)
Mar 2022
-
$13.60 M(+49.0%)
$2.64 M(-35.1%)
Dec 2021
$4.07 M(-95.6%)
$9.13 M(-14.4%)
$4.07 M(-90.8%)
Sep 2021
-
$10.66 M(-134.7%)
$44.41 M(-5.5%)
Jun 2021
-
-$30.74 M(-304.6%)
$46.98 M(-50.7%)
Mar 2021
-
$15.02 M(-69.6%)
$95.24 M(+2.1%)
Dec 2020
$93.24 M
$49.47 M(+273.8%)
$93.24 M(+75.7%)
DateAnnualQuarterlyTTM
Sep 2020
-
$13.23 M(-24.4%)
$53.07 M(+95.3%)
Jun 2020
-
$17.51 M(+34.5%)
$27.18 M(-120.5%)
Mar 2020
-
$13.03 M(+40.1%)
-$132.52 M(-9.0%)
Dec 2019
-$145.59 M(-512.6%)
$9.30 M(-173.4%)
-$145.59 M(-6.0%)
Sep 2019
-
-$12.66 M(-91.1%)
-$154.91 M(+8.6%)
Jun 2019
-
-$142.19 M(>+9900.0%)
-$142.59 M(>+9900.0%)
Mar 2019
-
-$44.00 K(+69.2%)
-$586.00 K(-101.7%)
Dec 2018
$35.29 M(-197.3%)
-$26.00 K(-92.2%)
$35.29 M(-4862.1%)
Sep 2018
-
-$333.00 K(+82.0%)
-$741.00 K(+40.3%)
Jun 2018
-
-$183.00 K(-100.5%)
-$528.00 K(+44.3%)
Mar 2018
-
$35.83 M(-199.4%)
-$366.00 K(-99.0%)
Dec 2017
-$36.28 M(+4945.5%)
-$36.05 M(>+9900.0%)
-$36.28 M(>+9900.0%)
Sep 2017
-
-$120.00 K(+471.4%)
-$223.00 K(+116.5%)
Jun 2017
-
-$21.00 K(-74.4%)
-$103.00 K(+25.6%)
Mar 2017
-
-$82.00 K
-$82.00 K
Dec 2016
-$719.00 K(+138.9%)
-
-
Dec 2015
-$301.00 K
-
-

FAQ

  • What is UroGen Pharma annual cash flow from investing activities?
  • What is the all time high annual CFI for UroGen Pharma?
  • What is UroGen Pharma annual CFI year-on-year change?
  • What is UroGen Pharma quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for UroGen Pharma?
  • What is UroGen Pharma quarterly CFI year-on-year change?
  • What is UroGen Pharma TTM cash flow from investing activities?
  • What is the all time high TTM CFI for UroGen Pharma?
  • What is UroGen Pharma TTM CFI year-on-year change?

What is UroGen Pharma annual cash flow from investing activities?

The current annual CFI of URGN is -$20.61 M

What is the all time high annual CFI for UroGen Pharma?

UroGen Pharma all-time high annual cash flow from investing activities is $93.24 M

What is UroGen Pharma annual CFI year-on-year change?

Over the past year, URGN annual cash flow from investing activities has changed by -$19.66 M (-2062.96%)

What is UroGen Pharma quarterly cash flow from investing activities?

The current quarterly CFI of URGN is $60.62 M

What is the all time high quarterly CFI for UroGen Pharma?

UroGen Pharma all-time high quarterly cash flow from investing activities is $60.62 M

What is UroGen Pharma quarterly CFI year-on-year change?

Over the past year, URGN quarterly cash flow from investing activities has changed by +$167.37 M (+156.79%)

What is UroGen Pharma TTM cash flow from investing activities?

The current TTM CFI of URGN is -$20.61 M

What is the all time high TTM CFI for UroGen Pharma?

UroGen Pharma all-time high TTM cash flow from investing activities is $95.24 M

What is UroGen Pharma TTM CFI year-on-year change?

Over the past year, URGN TTM cash flow from investing activities has changed by +$71.97 M (+77.73%)